Current Treatment Options in Third-line MCL

Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.